


Technical Information about N⁶,2'-O-Dibutyryl-cAMP (DB-cAMP)

Update: November 9, 2017 AI



Abbreviation: **DB-cAMP**

Formula	CAS No.	Molecular Weight	UV	BIOLOG Cat. No.
C ₁₈ H ₂₃ N ₅ O ₈ P·Na	[16980-89-5]	491.4	λ _{max} 273 nm / ε 17000 / pH 7	D 009

Name: N⁶,2'-O-Dibutyryladenine-3', 5'-cyclic monophosphate, Dibutyryl-cAMP, Dibutyryl cyclic AMP, Bucladesine, Actosin™, DBcAMP, Db-cAMP, bt₂-cAMP, BU₂-cAMP

Description: DB-cAMP is an analogue of the natural signal molecule cyclic AMP where both, the amino group in position 6 of the adenine nucleobase and the ribose 2'-hydroxyl group are modified with a butyrate moiety.

Bulk Supply: DB-cAMP can be offered in multigram quantities at extremely competitive prices. Please ask for a corresponding quotation.

Properties:

- Releases N⁶-monobutyryl-cAMP, an activator of protein kinase A, preferring type I of PKA.
- Increased metabolic stability towards cyclic nucleotide-responsive phosphodiesterases.
- Increased lipophilicity and membrane permeability while still soluble in aqueous solvents.

DB-cAMP is a common and widely used tool for proving the responsibility of cAMP for certain biological effects. However, in spite of the intensive use of this second messenger analogue there exist serious pitfalls which can falsify the results obtained with it.

In its native form DB-cAMP is nearly inactive towards protein kinase A, and needs to split off one of its butyryl groups at the ribose 2'-position in order to release the kinase-active N⁶-monobutyryl cAMP. Induced by esterases, this should normally take place inside the cell, but can also happen already in the medium if serum is used.

Unfortunately, the released butyrate induces a lot of effects which are often interfering with second messenger pathways. That means, that for each experiment with DB-cAMP, the influence of butyrate has to be determined in control runs with sodium butyrate or tributyrin.


Specification: Crystallized or lyophilized sodium salt. Other salt forms of DB-cAMP are available upon request. Please keep in mind that equal concentrations of the compound may look different in volume due to sensitivity of the lyophilized form to humidity. The compound can even contract to small volume droplets. Normally the product is located in the conical bottom of the tube. Micromolar quantities are determined by UV at λ_{max}.

Purity: Typical analysis is better than 98% (HPLC / UV / 273 nm). The product is not sterile and has not been tested for endotoxins.

Stability and Storage: DB-cAMP has sufficient stability at room temperature and does not need special care during handling or shipment. Nevertheless, we recommend that the compound should be stored in the freezer, for longer storage periods preferably in freeze-dried form.

Solubility: Detailed information on the solubility of DB-cAMP in water and various buffers are listed in the solubility chart below. Concentrations have been determined at ambient temperature and can be considered as minimum concentrations usually obtainable, however, slight batch-to-batch variations cannot be ruled out. When opening the tube please make sure that no substance is lost within the cap. Please rinse tube walls carefully and preferably use ultrasonic or vortex to achieve total and uniform mixing.

No.	Solvent	Solubility [mM]
I	H ₂ O	200
II	DMSO	200
III	DMF	200
IV	Ethanol 96%	25
V	Methanol	200
VI	PBS, pH 7.4	200
VII	100 mM Na ₂ HPO ₄ , pH 7.0	200
VIII	25 mM HEPES/NaOH, pH 7.2	200
IX	25 mM Tris/HCl, pH 7.4	200



Toxicity and Safety: Since cyclic AMP has multiple tasks in every organism, it is very likely that lipophilic cAMP analogues will interfere with many cell regulation processes *in vivo*. However, due to the rather small quantities to work with, no health hazards have been reported. Nevertheless please keep in mind, that the *in vivo* properties of this compound are not sufficiently characterized up to now. Avoid skin contact or ingestion and allow only trained personnel to handle the product.

Our products are designed, developed and sold for research purposes only! They are intended for *in vitro* and nonhuman *in vivo* laboratory applications. Any other use requires approval of health authorities.

Not for drug, household or related uses!

Selected References for DB-cAMP and butyrate problems: Since DB-cAMP is a well known biochemical structure there exist numerous citations for almost every biosystem. The following papers give basic information on various aspects of this molecule. For more information on the butyrate effects please visit our website www.biolog.de/technical_info_dbcamp-butyrate-pitfalls/.

Spaeth, C.S.; Boydston, E.A.; Figard, L.R.; Zuzek, A.; Bittner, G.D., *J. Neurosci.*, **30**, 15790 - 15800 (2010): "A Model for Sealing Plasmalemmal Damage in Neurons and Other Eukaryotic Cells"

Scheibner, K.A.; Boodoo, S.; Collins, S.; Black, K.E.; Chan-Li, Y.; Zarek, P.; Powell, J.D.; Horton, M.R., *Am. J. Respir. Cell Mol. Biol.*, **40**, 251 - 259 (2009): "The Adenosine A2a Receptor Inhibits Matrix Induced Inflammation in a Novel Fashion"

Brock, M.; Fan, F.; Mei, F.C.; Li, S.; Gessner, C.; Woods Jr. V.L.; Cheng, X., *J. Biol. Chem.*, **282**, 32256 - 32263 (2007): "Confirmational Analysis of Epac Activation Using Amide Hydrogen/Deuterium Exchange Mass Spectrometry"

Voisin, P.; Bernard, M., *J. Neurochem.*, **110**, 318 - 327 (2009): "Cyclic AMP-dependent Activation of Rhodopsin Gene Transcription in Cultured Retinal Precursor Cells of Chicken Embryo"

Meves, H., *Curr. Neuropharmacol.*, **4**, 41 - 57 (2006): "The Action of Prostaglandins in Ion Channels"

Bagley, K. C.; Abdelwahab, S. F.; Tuskan, R. G.; Fouts, T. R.; Lewis, G. K., *Infect. Immun.*, **70**, 5533 - 5539 (2002): "Cholera Toxin and Heat-Labile Enterotoxin Activate Human Monocyte-derived Dendritic Cells and Dominantly Inhibit Cytokine Production through a Cyclic AMP-dependent Pathway"

Johnston, C.A.; Beazely, M.A.; Vancura, A.F.; Wang, J.K.T.; Watts, V.J., *J. Neurochem.*, **82**, 1087 - 1096 (2002): "Heterologous Sensitization of Adenylate Cyclase is Protein Kinase A-dependent in Cath.a Differentiated (CAD)-D-2L Cells"

Steiner, A.A.; Antunes-Rodrigues, J.; Branco, L.G.S., *Brain Res.*, **944**, 135 - 145 (2002): "Role of Preoptic Second Messenger Systems (cAMP and cGMP) in the Febrile Response"

Yusta, B.; Ortiz-Caro, J.; Pascual, A.; Aranda, A., *J. Neurochem.*, **51**, 1808 (1988): "Comparison of the Effects of Forskolin and Dibutyryl Cyclic AMP in Neuroblastoma Cells: Evidence that Some of the Actions of Dibutyryl Cyclic AMP are Mediated by Butyrate"

Schaeffer, V.H.; Masoud, A.N.; Rubin, R.J., *J. Pharm. Sci.*, **72**, 1255 - 1259 (1983): "Analysis of Monobutyryl and Dibutyryl Derivatives of Adenosine 3',5'-monophosphate in Biological Samples using isocratic Ion Pair High-Performance Liquid Chromatography"

Peikin, S.R.; Costenbader, C.L.; Gardner, J.D., *J. Biol. Chem.*, **254**, 5321 - 5327 (1979): "Actions of Derivatives of Cyclic Nucleotides on Dispersed Acini from Guinea Pig Pancreas - Discovery of a Competitive Antagonist of the Action of Cholecystokinin"

Posternak, T.; Weimann, G., *Meth. Enzymol.*, **38**, 399 - 409 (1974): "[54] The Preparation of Acylated Derivatives of Cyclic Nucleotides"

Szabo, M.; Burke, G., *Biochem. Biophys. Acta*, **264**, 289 - 299 (1972): "Uptake and Metabolism of 3', 5' - Cyclic Adenosine Monophosphate and N6, 2'- O - Dibutyl- 3', 5' - Cyclic Adenosine Monophosphate in Isolated Bovine Thyroid Cells"

Kaukel, E.; Mundhenk, K.; Hiltz, H., *Eur. J. Biochemistry*, **27**, 197 - 200 (1972): "N6-Monobutyladenosine 3' : 5'- Monophosphate as the Biologically Active Derivative of Dibutyladenosine- 3': 5' - Monophosphate in HeLa S3 Cells"

Posternak, T.; Sutherland, E.W.; Henion, W.F., *Biochim. Biophys. Acta*, **65**, 558 - 560 (1962): "Derivatives of Cyclic 3',5'- Adenosine Monophosphate"